AU2011276955B2 - Protein kinase inhibitors and methods of treatment - Google Patents

Protein kinase inhibitors and methods of treatment Download PDF

Info

Publication number
AU2011276955B2
AU2011276955B2 AU2011276955A AU2011276955A AU2011276955B2 AU 2011276955 B2 AU2011276955 B2 AU 2011276955B2 AU 2011276955 A AU2011276955 A AU 2011276955A AU 2011276955 A AU2011276955 A AU 2011276955A AU 2011276955 B2 AU2011276955 B2 AU 2011276955B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
compound
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011276955A
Other languages
English (en)
Other versions
AU2011276955A1 (en
Inventor
Jonathan Bayldon Baell
Antony Wilks Burgess
Guillaume Laurent Lessene
Hiroshi Maruta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of AU2011276955A1 publication Critical patent/AU2011276955A1/en
Application granted granted Critical
Publication of AU2011276955B2 publication Critical patent/AU2011276955B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2011276955A 2010-07-09 2011-07-08 Protein kinase inhibitors and methods of treatment Ceased AU2011276955B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36273910P 2010-07-09 2010-07-09
US61/362,739 2010-07-09
PCT/AU2011/000858 WO2012003544A1 (en) 2010-07-09 2011-07-08 Protein kinase inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
AU2011276955A1 AU2011276955A1 (en) 2013-01-24
AU2011276955B2 true AU2011276955B2 (en) 2014-11-06

Family

ID=45440707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011276955A Ceased AU2011276955B2 (en) 2010-07-09 2011-07-08 Protein kinase inhibitors and methods of treatment

Country Status (6)

Country Link
US (1) US8962830B2 (cg-RX-API-DMAC10.html)
EP (1) EP2590982B1 (cg-RX-API-DMAC10.html)
JP (1) JP5810157B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011276955B2 (cg-RX-API-DMAC10.html)
CA (1) CA2804648C (cg-RX-API-DMAC10.html)
WO (1) WO2012003544A1 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN102977012B (zh) * 2012-12-20 2015-06-03 江苏弘和药物研发有限公司 4-溴吡啶-2-甲酸甲酯的合成方法
EP2970291B1 (en) * 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN103965201A (zh) * 2014-04-30 2014-08-06 淮海工学院 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10196397B2 (en) 2014-11-19 2019-02-05 Sun Pharmaceutical Industries Limited Process for the preparation of ibrutinib
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076986A1 (en) * 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
WO2002080926A1 (en) * 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US20070293516A1 (en) * 2006-04-04 2007-12-20 Regents Of The University Of California Kinase antagonists
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2010009342A2 (en) * 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076986A1 (en) * 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
WO2002080926A1 (en) * 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US20070293516A1 (en) * 2006-04-04 2007-12-20 Regents Of The University Of California Kinase antagonists
WO2008039218A2 (en) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2010009342A2 (en) * 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
APSEL, B. et al, Nature Chemical Biology, 2008, vol. 4 (11), pp. 691-699 *

Also Published As

Publication number Publication date
JP5810157B2 (ja) 2015-11-11
EP2590982A1 (en) 2013-05-15
CA2804648C (en) 2019-01-22
US20130184274A1 (en) 2013-07-18
EP2590982B1 (en) 2017-08-23
WO2012003544A1 (en) 2012-01-12
JP2013529649A (ja) 2013-07-22
AU2011276955A1 (en) 2013-01-24
US8962830B2 (en) 2015-02-24
CA2804648A1 (en) 2012-01-12
EP2590982A4 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
AU2011276955A1 (en) Protein kinase inhibitors and methods of treatment
TWI399380B (zh) 抗病毒化合物
US11192900B2 (en) Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
CN105408324A (zh) 取代的苄基吡唑
JP2009502734A (ja) Ｌｃｋ阻害剤としての縮合複素環
CN105452242A (zh) 杂芳基取代的吡唑
EP2922857B1 (en) Thioether derivatives as protein kinase inhibitors
EP4089089A1 (en) Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof
US10308654B2 (en) Preparation and use of kinase inhibitor
CN110167943B (zh) 作为激酶抑制剂的吡咯并三嗪衍生物
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
CN112839930A (zh) 作为flt3和axl抑制剂的3,9-二氮杂螺[5, 5]十一烷类化合物
WO2025139240A1 (zh) Parp7抑制剂及其用途
US8822698B2 (en) Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN107721937B (zh) 含有嘧啶酮骨架的化合物的制备方法和用途
CN116535422B (zh) 具有五元芳杂环并哌啶/高哌啶的hpk1抑制剂及其制备方法及用途
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
WO2026021342A1 (zh) 一种杂环类化合物及其在医药上的应用
CN118666823A (zh) 作为Kif18A抑制剂的化合物
CN112209933A (zh) 含有4-氮杂螺庚烷的btk抑制剂
HK40006200B (en) Pyrrolotriazine derivatives as kinase inhibitor
HK40006200A (en) Pyrrolotriazine derivatives as kinase inhibitor
CN114380841A (zh) 作为akt抑制剂的三环喹唑啉或二氢喹唑啉化合物
Dono et al. Maina et al.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired